Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Should You Buy T. Rowe Price Group, Inc. (NASDAQ:TROW)?

Is T. Rowe Price Group, Inc. (NASDAQ:TROW) a buy here? The smart money is becoming more confident. The number of long hedge fund bets improved by 3 in recent months.

T. Rowe Price Group, Inc.

In today’s marketplace, there are tons of gauges shareholders can use to track stocks. Two of the most useful are hedge fund and insider trading interest. At Insider Monkey, our research analyses have shown that, historically, those who follow the best picks of the best investment managers can outperform the market by a healthy margin (see just how much).

Equally as beneficial, positive insider trading sentiment is a second way to parse down the marketplace. As the old adage goes: there are lots of motivations for an insider to get rid of shares of his or her company, but only one, very simple reason why they would initiate a purchase. Many empirical studies have demonstrated the valuable potential of this tactic if piggybackers understand where to look (learn more here).

Consequently, let’s take a glance at the latest action surrounding T. Rowe Price Group, Inc. (NASDAQ:TROW).

How have hedgies been trading T. Rowe Price Group, Inc. (NASDAQ:TROW)?

Heading into 2013, a total of 24 of the hedge funds we track were bullish in this stock, a change of 14% from one quarter earlier. With hedgies’ sentiment swirling, there exists a few key hedge fund managers who were increasing their stakes substantially.

When looking at the hedgies we track, Citadel Investment Group, managed by Ken Griffin, holds the largest position in T. Rowe Price Group, Inc. (NASDAQ:TROW). Citadel Investment Group has a $48 million position in the stock, comprising 0.1% of its 13F portfolio. The second largest stake is held by Chuck Royce of Royce & Associates, with a $31 million position; 0.1% of its 13F portfolio is allocated to the company. Other hedge funds that are bullish include Israel Englander’s Millennium Management, John W. Rogers’s Ariel Investments and Tom Gayner’s Markel Gayner Asset Management.

Consequently, some big names were breaking ground themselves. SAC Capital Advisors, managed by Steven Cohen, established the biggest position in T. Rowe Price Group, Inc. (NASDAQ:TROW). SAC Capital Advisors had 12 million invested in the company at the end of the quarter. George Soros’s Soros Fund Management also made a $10 million investment in the stock during the quarter. The following funds were also among the new TROW investors: Jim Simons’s Renaissance Technologies, Ken Gray and Steve Walsh’s Bryn Mawr Capital, and Glenn Russell Dubin’s Highbridge Capital Management.

What do corporate executives and insiders think about T. Rowe Price Group, Inc. (NASDAQ:TROW)?

Insider buying is best served when the company in question has experienced transactions within the past 180 days. Over the last 180-day time period, T. Rowe Price Group, Inc. (NASDAQ:TROW) has seen zero unique insiders purchasing, and 4 insider sales (see the details of insider trades here).

With the returns exhibited by the aforementioned research, retail investors must always watch hedge fund and insider trading activity, and T. Rowe Price Group, Inc. (NASDAQ:TROW) is no exception.

Click here to learn more about Insider Monkey’s Hedge Fund Newsletter

Insider Monkey’s small-cap strategy returned 29.2% between September 2012 and February 2013 versus 8.7% for the S&P 500 index. Try it now by clicking the link above.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!